FDA Approves Galafold (migalastat) for the Treatment of Fabry Disease

August 10, 2018 -- The U.S. Food and Drug Administration today approved Galafold (migalastat), the first oral medication for the treatment of adults with Fabry disease. The drug is indicated for adults with Fabry disease who have a genetic mutation...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news